EGFR and cancer: In addition, affibody molecules tolerate modifications and conjugations with retained high-target affinity, and the absence of disulfide bridges in the structure make them convenient to be used as a part of complex molecules (Friedman et al., 2008).Therefore, the affibody can be successfully used to deliver cytotoxic agents to the nuclei of cancer cells with EGFR expression.